drugset / Trial / NCT03056118
Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents
RandomizedFactorialSingle-blindTreatment
Summary
Investigators try to assess the safety of 6-months or 12-months maintenance of dual antiplatelet therapy (DAPT, aspirin + clopidogrel) in patients undergoing percutaneous coronary intervention using the Zotarolimus-eluting, Resolute Integrity™ stent (Medtronic Vascular Inc, Santa Rosa, CA) or the BioMatrix™ stent (Biosensors. Singapore).
Timeline
- Start
- 2011-05-02
- Primary completion
- 2015-06-01
- Completion
- 2015-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | — | — |
| Subject | Clopidogrel | Small molecule | — | — |